دورية أكاديمية
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes.
| العنوان: | Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes. |
|---|---|
| المؤلفون: | Di Folco U; Diabetes Unit, 'S. Camillo-Forlanini' Hospital, Rome, Italy. difolcougo@gmail.com., Vallecorsa N; Diabetes Unit, 'S. Camillo-Forlanini' Hospital, Rome, Italy., Nardone MR; Diabetes Unit, 'S. Camillo-Forlanini' Hospital, Rome, Italy., Pantano AL; Diabetes Unit, 'S. Camillo-Forlanini' Hospital, Rome, Italy., Tubili C; Diabetes Unit, 'S. Camillo-Forlanini' Hospital, Rome, Italy. |
| المصدر: | Acta diabetologica [Acta Diabetol] 2022 Oct; Vol. 59 (10), pp. 1287-1294. Date of Electronic Publication: 2022 Jul 17. |
| نوع المنشور: | Journal Article; Observational Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Berlin : Springer Verlag Original Publication: Berlin : Springer International, c1991- |
| مواضيع طبية MeSH: | Cardiovascular Diseases*/epidemiology , Cardiovascular Diseases*/etiology , Cardiovascular Diseases*/prevention & control , Diabetes Mellitus, Type 2*/complications , Diabetes Mellitus, Type 2*/drug therapy, Aged ; Antihypertensive Agents/therapeutic use ; Feeding Behavior ; Female ; Glucagon-Like Peptides ; Glycated Hemoglobin/metabolism ; Heart Disease Risk Factors ; Humans ; Hypoglycemic Agents/therapeutic use ; Male ; Middle Aged ; Risk Factors |
| مستخلص: | Aims: Aim of the present study was to evaluate the impact of once-weekly semaglutide on different end-points indicative of metabolic control, cardiovascular risk, dietary behavior, and treatment satisfaction in T2DM. Methods: This was a retrospective observational study conducted in a diabetes clinic. Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed. Furthermore, at T1 patients were asked to fill-in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Control of Eating Questionnaire (COEQ). Results: Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years). After 32 weeks of treatment with semaglutide, HbA1c levels were reduced by 1.38%, FBG by - 56.53 mg/dl, weight by 6.03 kg. Systolic and diastolic blood pressure, total, HDL-, LDL-, and non -HDL cholesterol, and triglycerides significantly improved. The number of glucose-lowering and antihypertensive drugs also decreased. At T1, DTSQ score was 32.23 ± 1.44, whereas COEQ indicated low levels of hunger and good control of eating. Conclusions: The study documented benefits of semaglutide on metabolic control and multiple CV risk factors, simplification of therapeutic schemes and high satisfaction with diabetes treatment, and eating behaviors indicative of healthy diet and reduced food intake. (© 2022. The Author(s).) |
| التعليقات: | Comment in: Acta Diabetol. 2023 May;60(5):715-716. (PMID: 36899150) |
| References: | International Diabetes Federation. IDF Diabetes Atlas. 7th ed. IDF Web site. IDF, 2015. Accessed August 16, 2017. Nauck MA, Keine N, Orscov, et al (1993) Normalization of fasting Hyperglycaemia by exogenous glucagon-like peptide 1 in type 2 diabetic patients. Diabetologia 36:741–744. (PMID: 10.1007/BF004011458405741) Raccah D, Chou E, Colagiuri S et al (2017) A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin. Diabetes Metab Res Rev. https://doi.org/10.1002/dmrr.2858. (PMID: 10.1002/dmrr.285827606888) Flint A, Raben A, Astrup A, Holst JJ (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515–520. (PMID: 10.1172/JCI9909449682508592) Gutzwiller JP, Drewe J, Goke B et al (1999) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276:R1541–R1544. (PMID: 10233049) Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP (2012) The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J Neurosci 32:4812–4820. (PMID: 10.1523/JNEUROSCI.6326-11.2012224920366620919) Hjerpsted JB, Flint A et al (2018) Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab 20:610–619. (PMID: 10.1111/dom.1312028941314) Ram N, Ahmed B, Hashmi F, Jabbar A (2014) Importance of measuring Non-HDL cholesterol in type 2 diabetes patients. J Pak Med Assoc 64:124–128. (PMID: 24640797) Eliasson B, Cederholm J, Eeg-Olofsson K, Svensson AM, Zethelius B, Gudbjörnsdottir S, Register ND (2011) Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: a report from the Swedish national diabetes Register. Diabetes Care 34:2095–2100. (PMID: 10.2337/dc11-0209217757503161275) Brunner FJ, Waldeyer C, Ojeda F et al (2019) Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet 394:2173–2183. (PMID: 10.1016/S0140-6736(19)32519-X318106096913519) Carr SS, Hooper AJ, Sullivan DR, Burnett JR (2019) Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology 5:148–154. (PMID: 10.1016/j.pathol.2018.11.006) Grundy SM, Cleeman JI, Merz CN et al (2004) (2016) Implications of recent clinical trials for the National Cholesterol education program adult treatment panel III guidelines. Circulation 110:227–239. (PMID: 10.1161/01.CIR.0000133317.49796.0E15249516) Marso SP, Bain SC, Consoli A et al (2016) SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844. (PMID: 10.1056/NEJMoa160714127633186) Blundell J, Finlayson G, Axelsen MB et al (2017) Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 19:1242–1251. (PMID: 10.1111/dom.12932282667795573908) Bradley C (1994) Diabetes treatment satisfaction questionnaire (DTSQ). In: Bradley C (ed) Handbook of psychology and diabetes. Harwood Academy Publisher, Amsterdam, pp 111–132. Nicolucci A, Giorgino R, Cucinotta D et al (2004) Validation of the Italian version of the WHO well-being questionnaire (WHO-WBQ) and the WHO-diabetes treatment satisfaction questionnaire (WHO-DTSQ). Diabet Nutr Metab 17:235–243. Hill AJ, Weaver CF, Blundell JE (1991) Food craving, dietary restraint and mood. Appetite 17:187–197. (PMID: 10.1016/0195-6663(91)90021-J1799281) Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB (2017) Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 19:1242–1251. (PMID: 10.1111/dom.12932282667795573908) Ahmann A, Chow F, Vivian F, et al (2018) Semaglutide provides superior glycemic control across SUSTAIN 1–5 clinical trials. Int J Nutrol, 11(01):Trab722. Mann JFE, Hansen T, Idorn T et al (2020) Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Lancet Diabetes Endocrinol 8:880–893. (PMID: 10.1016/S2213-8587(20)30313-232971040) Brown RE, Bech PG, Aronson R (2020) Semaglutide once weekly in people with type 2 diabetes: real-world analysis of the Canadian LMC diabetes registry (SPARE study). Diabetes Obes Metab 22:2013–2020. (PMID: 10.1111/dom.14117325385417689820) Jain AB, Kanters S, Khurana R, Kissock J, Severin N, Stafford SG (2021) Effectiveness analysis of switching from liraglutide or dulaglutide to semaglutide in patients with type 2 diabetes mellitus: the retrospective REALISE-DM study. Diabetes Ther 12:527–536. (PMID: 10.1007/s13300-020-00984-x33367981) Lingvay I, Kirk AR, Lophaven S, Wolden ML, Shubrook JH (2021) Outcomes in GLP-1 RA-Experienced patients switching to once-weekly semaglutide in a real-world setting: the retrospective, observational expert study. Diabetes Ther 12:879–896. (PMID: 10.1007/s13300-021-01010-4335945827947062) Visaria J, Uzoigwe C, Swift C, Dang-Tan T, Paprocki Y, Willey VJ (2021) Real-world effectiveness of once-weekly semaglutide from a US commercially insured and medicare advantage population. Clin Ther 43:808–821. (PMID: 10.1016/j.clinthera.2021.03.00333785221) Rajamand Ekberg N, Bodholdt U, Catarig AM et al (2021) Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Denmark/Sweden multicentre, prospective, observational study. Prim Care Diabetes 15:871–878. (PMID: 10.1016/j.pcd.2021.06.00834183269) Hansen KB, Svendstrup M, Lund A, Knop FK, Vilsbøll T, Vestergaard H (2021) Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: real-world data from a diabetes out-patient clinic. Diabet Med 38:e14655. (PMID: 10.1111/dme.1465534291491) Di Loreto C, Minarelli V, Nasini G, Norgiolini R, Del Sindaco P (2022) Effectiveness in real-word of once weekly semaglutide in people with type 2 diabetes glucagon-like peptide receptor agonists naïve or switchers from other glucagon-like peptide receptor agonists: results from a retrospective observational Umbria Study. Diabetes Ther 13:551–567. (PMID: 10.1007/s13300-022-01218-y352306508886341) Zobel EH, von Scholten BJ, Hansen TW et al (2022) The importance of addressing multiple risk markers in type 2 diabetes: results from the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab 24:281–288. (PMID: 10.1111/dom.1457834676658) AMD SID Linea Guida della Società Italiana di Diabetologia (SID) e dell’Associazione dei Medici Diabetologi (AMD). La terapia del diabete mellito di tipo 2. (2021). https://www.siditalia.it/pdf/LG_379_diabete_2_sid_amd.pdf [Italian[. Last access March 3rd, 2022. American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al (2022) 1. Improving care and promoting health in populations: standards of medical care in diabetes-2022. Diabetes Care, 45(Supplement_1):S8-S16. World Health Organization. Overweight and Obesity. 2018. http://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight . Accessed 10 June 2019. Pintaudi B, Scatena A, Piscitelli G et al (2021) Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study. Cardiovasc Diabetol 20:59. (PMID: 10.1186/s12933-021-01251-4336764997936493) Nicolucci A, Rossi MC (2008) Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomed 79:184–191. (PMID: 19260377) Iqbal J, Wu HX, Hu N et al (2022) Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obes Rev. https://doi.org/10.1111/obr.13435. (PMID: 10.1111/obr.1343535194917) Harder H, Nielsen L, Tu DT, Astrup A (2004) The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabet Care 27:1915–1921. (PMID: 10.2337/diacare.27.8.1915) Pratley RE, Aroda VR, Lingvay I et al (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabet Endocrinol 6:275–286. (PMID: 10.1016/S2213-8587(18)30024-X) Capehorn MS, Catarig AM, Furberg JK et al (2020) Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabet Metab 46:100–109. (PMID: 10.1016/j.diabet.2019.101117) Khunti K, Millar-Jones D (2017) Clinical inertia to insulin initiation and intensification in the UK: a focused literature review. Prim Care Diabet 11:3–12. (PMID: 10.1016/j.pcd.2016.09.003) Davies M, Speight J (2012) Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes Obes Metab 14:882–892. (PMID: 10.1111/j.1463-1326.2012.01595.x22420869) Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Baekdal T (2021) Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab 23:581–588. (PMID: 10.1111/dom.1425533184979) Ahmann AJ, Capehorn M, Charpentier G et al (2018) Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabet Care 41:258–266. (PMID: 10.2337/dc17-0417) Evert AB, Boucher JL, Cypress M et al (2014) Nutrition therapy recommendations for the management of adults with diabetes. Diabet Care 37(Suppl 1):S120-143. (PMID: 10.2337/dc14-S120) |
| فهرسة مساهمة: | Keywords: Eating behaviors HbA1c; Effectiveness; Hyperglycemia; Non-HDL cholesterol; Semaglutide; Treatment satisfaction; Type 2 diabetes; Weight |
| المشرفين على المادة: | 0 (Antihypertensive Agents) 0 (Glycated Hemoglobin A) 0 (Hypoglycemic Agents) 53AXN4NNHX (semaglutide) 62340-29-8 (Glucagon-Like Peptides) |
| تواريخ الأحداث: | Date Created: 20220717 Date Completed: 20220826 Latest Revision: 20230718 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9288662 |
| DOI: | 10.1007/s00592-022-01936-6 |
| PMID: | 35842847 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-5233 |
|---|---|
| DOI: | 10.1007/s00592-022-01936-6 |